Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 0904-7582

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 0904-7582). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label Of 30 Tablets (Sacu 24 26 30)

This is a description of a unit dose of Sacubitril and Valsartan tablets containing 24 mg of sacubitril monosodium and 26 mg of valsartan disodium, with each tablet equivalent to 26 mg of sacubitril and 28.3 mg of valsartan. The package contains 30 tablets and should be stored at temperatures ranging from 20°C to 25°C (68°F to 77°F), with limited excursions between 5°C to 30°C (41°F to 86°F). It is important to protect the tablets from moisture and keep them out of reach of children. Please see prescribing information for usual dosage.*

FDA Label Image

Carton Label Of 30 Tablets (Sacu 49 51 30)

This text appears to be a description of a medication called Sacubitril and Valsartan, presented in tablets form with a dosage of 49 mg of Sacubitril and 51 mg of Valsartan. The medication is packaged in 30 tablets in a unit dose format, meaning it is divided into individual doses. The recommended storage conditions are between 15°C to 25°C (59°F to 77°F) to protect from moisture. The text also includes information about the controlled room temperature and advising to keep the medication out of reach of children. The medication is intended for prescription use only.*

FDA Label Image

Sacu-97-103-30-a (Sacu 97 103 30 A)

Description: This text provides information about a unit dose pack of Sacubitril and Valsartan tablets. It includes details about the product code, dosage, storage instructions, manufacturer, and distributor. The medication is intended for prescription use only and the usual dosage guidance is recommended to be followed. The text also mentions the temperature range for storage and protection from moisture. The product is manufactured by Alkom Laboratories Ltd. in Mumbai, India, and distributed by Major Pharmaceuticals in Indianapolis, USA.*

FDA Label Image

Sacu-fig-a-1 (Sacu Fig A 1)

The text shows a Figure A illustrating the Time to First Occurrence of Cardiovascular (CV) Death or Heart Failure Hospitalizations in the PARADIGM-HF trial. The data includes p-values, Hazard Ratios (HR) with 95% Confidence Intervals, and compares Sacubitril and Valsartan with Enalapril over time since randomization in days. The results indicate statistical significance (p<0.0001) in favor of Sacubitril and Valsartan with a lower HR compared to Enalapril.*

FDA Label Image

Sacu-fig-b-1 (Sacu Fig B 1)

The text provides information on the Time to Occurrence of CV Death in the PARADIGM-HF study. It presents data on Hazard Ratio (HR) with a confidence interval, as well as the number of patients at risk over different time intervals since randomization. The study appears to compare Sacubitril and Valsartan with Enalapril in relation to cardiovascular outcomes.*

FDA Label Image

Sacu-fig-c-2 (Sacu Fig C 2)

This text provides information on the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF trial. The data includes hazard ratios with corresponding confidence intervals comparing Sacubitril and Valsartan to Enalapril. It also presents the number of patients at risk over time since randomization in days.*

FDA Label Image

Sacu-figure-4-c (Sacu Figure 4 C)

This document appears to be a summary showing various subgroups within a population and their corresponding percentages for different parameters such as age, gender, weight, race, comorbidities like diabetes and hypertension, blood pressure levels, presence of atrial fibrillation, prior medication use, heart failure hospitalization, and cause of heart failure. Additionally, it looks at factors like estimated GFR, systolic blood pressure levels, and time since the diagnosis of heart failure. This data seems to be related to the evaluation of Sacubitril and Valsartan compared to Enalapril in the context of heart failure treatment.*

FDA Label Image

Sacu-figure1 (Sacu Figure1)

This is a list of coadministered drugs along with specific details such as Geometric Mean Ratio and 90% Confidence Interval. These drugs include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The information provided likely relates to the pharmacokinetics or drug interactions of these medications when taken together.*

FDA Label Image

Sacu-figure2 (Sacu Figure2)

FDA Label Image

Sacu-figure5-a (Sacu Figure5 A)

FDA Label Image

Sacu-figure6-a (Sacu Figure6 A)

FDA Label Image

Sacu-figure7 (Sacu Figure7)

FDA Label Image

Structure (Sacu Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.